logo
Iodine Software Launches Next-Generation Pre-Bill Solution to Help Health Systems Right-Size Reimbursement

Iodine Software Launches Next-Generation Pre-Bill Solution to Help Health Systems Right-Size Reimbursement

Business Wire15-05-2025
AUSTIN, Texas--(BUSINESS WIRE)--Iodine Software, the leader in healthcare AI for revenue cycle optimization, today launched the next generation of its pre-bill solution, AwarePre-Bill, designed to help health systems close critical revenue gaps before claims are submitted. Built on years of proven success, the solution enables health systems to conduct financially targeted retrospective reviews, improving code accuracy and documentation to help right-size reimbursement. With Iodine, clients have captured $3–4 million per month in previously missed revenue.
The launch comes at a time when health systems are under immense financial pressure. Claims denials have risen 16% over the past six years, and nearly 40% of hospitals operate at a deficit. Although more than 80% of appealed denials are ultimately overturned, limited resources prevent many systems from pursuing them—leaving millions in revenue on the table. Increasingly, hospitals are turning to AI-driven solutions like Iodine's to address these gaps and ensure financial sustainability in an increasingly complex payer environment.
'Iodine's pre-bill technology has delivered measurable ROI for AdventHealth,' said Dr. Christopher Riccard, VP of Hospital Medicine and CDI at AdventHealth. 'We've seen a meaningful lift in high-impact queries that drive both revenue and quality outcomes. The ability to prioritize the right cases—not just more—has transformed our teams' productivity and strengthened our financial performance.'
The solution leverages proven AI to pinpoint patient records with the greatest financial impact, exclude low-value cases, and validate DRG and ICD-10 codes by identifying missing documentation, recommending more appropriate codes, and surfacing alternative principal diagnoses. It also identifies post-discharge query opportunities, flags diagnoses lacking sufficient physician support, and detects financially significant quality events—such as HACs and PSIs—that may warrant documentation or coding updates. Each recommendation is backed by relevant clinical context, enabling reviewers to act with speed, accuracy, and confidence.
Recognizing the persistent staffing challenges facing health systems, Iodine will also offer tech-enabled services to help close pre-bill revenue gaps.
'Hospitals are navigating rising denial rates and shrinking margins,' said William Chan, CEO of Iodine Software. 'We remain focused on our mission to be a true partner in helping health systems get reimbursed accurately for the care they provide. With enhanced pre-bill capabilities and flexible, outcomes-based pricing and service models, we are making it easier for healthcare leaders to adopt the tools they need to safeguard financial performance and support long-term stability.'
Today, hundreds of health systems rely on Iodine to improve cycle revenue performance—reducing review times by 63% and generating millions in incremental impact annually. As Chan notes, 'In an environment where every dollar counts, we're delivering the tools hospitals need to protect their margins—and their mission.'
For more information on Iodine Software and its industry-leading AI solutions, visit www.iodinesoftware.com.
About AdventHealth
AdventHealth is a connected network of care that helps people feel whole – body, mind and spirit. More than 100,000 team members across a national footprint provide whole-person care to nearly nine million people annually through more than 2,000 care sites that include hospitals, physician practices, ambulatory surgery centers, outpatient clinics, home health agencies, hospice centers, the AdventHealth app and more. Our wholistic approach to improving the health and prosperity of our communities is inspired by our mission to extend the healing ministry of Christ.
About Iodine Software
Iodine Software is the leader in AI-powered clinical intelligence, helping healthcare organizations capture the full value of patient care. Our solutions drive accurate documentation, optimize reimbursement, reduce administrative burden, and help prevent costly denials—powering more efficient revenue cycle operations. For over a decade, health systems have trusted Iodine to apply the right AI—whether machine learning, deep learning, GenAI and Agentic AI— to the right use case, consistently delivering reliable, high-impact outcomes.
Iodine's proprietary Clinical Intelligence Engine, CognitiveML, mirrors clinical judgment and draws insights from one of the largest sets of inpatient clinical data in the country. The platform continuously reviews every patient chart to deliver the most holistic, real-time clinical snapshot available. Recognized as Best in KLAS, Iodine's Clinical Intelligence Suite scales clinical intelligence through solutions like AwareCDI, AwareUM, and AwarePre-Bill, helping healthcare organizations achieve financial returns and improve quality. Learn more at www.iodinesoftware.com.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

LeafWorks Expands Botanical Species ID Testing to Cover the Top 75 Herbs and Fungi for Natural Products and Foods
LeafWorks Expands Botanical Species ID Testing to Cover the Top 75 Herbs and Fungi for Natural Products and Foods

Business Wire

time6 minutes ago

  • Business Wire

LeafWorks Expands Botanical Species ID Testing to Cover the Top 75 Herbs and Fungi for Natural Products and Foods

SEBASTOPOL, Calif.--(BUSINESS WIRE)-- LeafWorks, a trailblazing botanical genomics and testing company for natural products, today announced the expansion of its DNA-based species identification services to include the most widely used herbs and fungi in natural products and foods, and their common adulterants. 'The natural products industry has long faced significant gaps in robust identification testing for challenging herbs and complex formulations. Our genetic approach fills those gaps,' - Kerin Law, Ph.D., LeafWorks Chief Scientific Officer Share In an industry where DNA testing options are lacking yet identification problems persist, this is a significant leap forward in botanical identification capabilities. The new DNA testing options give product manufacturers and sourcing managers an accurate, scalable way to confirm botanical identity—whether validating a single species or identifying multiple plant and fungal components in complex formulations. The expanded Botanical ID Testing service now offers two formats of species identification: LeafWorks® Botanical DNA ID Tests —Confirms whether a sample contains a specific species, answering the question, 'Is this the species I think it is?' LeafWorks® Adulteration DNA ID Testing —Detects common adulterants or substitutions used in natural products which can escape visual or chemistry-based detection. These are also species commonly used in many food products such as peanut, rice and wheat. These tests focus on providing reliable and robust ID testing options for the top 75 herbs and fungi in natural products, as well as common and product-specific adulterants, to solve a comprehensive scope of identification needs. Validated against a global genomic library with thousands of authenticated Botanical Reference and Certified Reference Materials—including common lookalikes, closely related sister species and adulterants—these sequencing-based tests meet 21 CFR Part 111 requirements for third-party identity verification and support full supply chain traceability. Adulteration is common in the global botanical trade, whether intentional or a byproduct of complex supply chains, such as mistaken identity. LeafWorks' DNA-based testing helps manufacturers safeguard product integrity, make informed sourcing decisions, ensure label accuracy, reduce regulatory risk, and maintain compliance. 'The natural products industry has long faced significant gaps in robust identification testing for challenging herbs and complex formulations. Our genetic approach fills those gaps,' said Kerin Law, Ph.D., LeafWorks' Chief Scientific Officer. 'DNA cannot be masked or changed. If it's present, even at trace levels, we will find it and accurately identify it using our industry-leading genomic database that took years to build with thousands of reference materials. Our clients need reliable answers, and this testing delivers exactly that.' Unlike other methods such as microscopy or macroscopy—which struggle to identify ingredients in highly processed or derived materials—or chemistry-based tests, which can miss ingredients with overlapping profiles or masked compounds, DNA analysis targets the underlying genetic code itself. As a stable, discrete material, DNA remains unaffected by cultivation conditions or the bringing together of multiple ingredients. Challenges in current identification methods are especially acute for blended products with multiple species where misidentification risk is higher — yet this is where DNA testing excels. 'DNA is built for testing identity. Development of orthogonal DNA-based identification methods that look at entire genomes and move beyond problematic barcodes or marker types will add a depth of certainty currently lacking in many species,' said LeafWorks CEO Eleanor Kuntz, Ph.D. LeafWorks' advantage goes beyond its industry-leading DNA database. By focusing on areas of the genome that are unique to each species, the company ensures the highest accuracy. Its substantial investment in a proprietary database and advanced bioinformatics pipeline enables rapid identification of these species-specific markers across thousands of samples at once, delivering unmatched precision in species identification. By integrating genomic science into routine quality control workflows, LeafWorks provides manufacturers with actionable data that supports both regulatory compliance and consumer trust. These tests help quality-assurance and quality-control teams verify ingredient identity, guide product development, assess purity, and give sourcing managers the confidence to purchase large global shipments knowing they have the correct material. 'Having reliable testing options is critical for satisfying label requirements such as 21 CFR 111, and designing a robust test takes careful genomic R&D,' added Laura Klein, Ph.D., Director of Herbal Research. 'We're proud to expand our testing to cover the top herbs and fungi used across the natural products industry, backed by rigorous methodology.' LeafWorks' Botanical ID Testing is immediately available to customers in the dietary supplements, herbal medicine, foods, cosmetics, and natural products across a diverse array of product types. For more information or to inquire about testing, visit or contact info@ About LeafWorks LeafWorks Inc. is a botanical genomics company conducting cutting-edge research and developing commercial DNA testing services for natural products. Co-founded by CEO Eleanor Kuntz, Ph.D., and CSO Kerin Law, Ph.D., the company combines scientific rigor with uncompromising ethics, specializing in DNA identification—from species ID down to trait detection—to protect and empower business operators. The company provides the necessary testing and services that help cultivators preserve their genetic IP, improve efficiency and ultimately evolve their operations. Learn more about LeafWorks Inc. at and connect on Facebook, Instagram, X and LinkedIn.

CILA Therapeutics Awarded NCATS Grant to Advance a Transformational Platform That Significantly Enhances Inhaled Delivery of RNA-LNP Into Lung Cells
CILA Therapeutics Awarded NCATS Grant to Advance a Transformational Platform That Significantly Enhances Inhaled Delivery of RNA-LNP Into Lung Cells

Business Wire

time6 minutes ago

  • Business Wire

CILA Therapeutics Awarded NCATS Grant to Advance a Transformational Platform That Significantly Enhances Inhaled Delivery of RNA-LNP Into Lung Cells

BOSTON--(BUSINESS WIRE)-- CILA Therapeutics has been awarded a competitive grant from the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH), to advance the development of its proprietary CIL-Key™ platform — a novel, gene-agnostic delivery technology that significantly and reproducibly enhances the transfection efficiency and delivery of inhaled RNA-loaded lipid nanoparticles (RNA-LNPs) into lung epithelial cells. 'This milestone provides strong validation of CILA's scientific approach and vision to deliver practical, scalable and patient-centric solutions for some of the most formidable challenges in pulmonary medicine," said Safia Rizvi, CEO, CILA Therapeutics Share In preclinical studies, the CIL-Key™ platform (also referred to as CIL-0X in the grant) achieved up to a 430% increase in delivery of functionally intact RNA into human bronchial epithelial cells cultured at an air-liquid interface (ALI), demonstrating utility across multiple RNA-LNP formulations. 'This milestone provides strong validation of CILA's scientific approach and vision to deliver practical, scalable and patient-centric solutions for some of the most formidable challenges in pulmonary medicine,' said Safia Rizvi, CEO of CILA Therapeutics. CIL-Key™ is designed to enable efficient, localized intracellular delivery of RNA-based modalities while minimizing systemic exposure. The platform could offer significant advantages for companies developing inhaled RNA therapies and vaccines for a broad range of lung diseases, including Primary Ciliary Dyskinesia (PCD), Cystic Fibrosis (CF), COPD and Pulmonary Fibrosis, as well as respiratory infections including influenza, RSV and COVID-19. Chronic pulmonary diseases affect more than 34 million people in the U.S. and more than 545 million globally. These often progressive, life-limiting conditions have a significant impact on quality of life and a high economic burden, creating an urgent demand for novel, effective and easy-to-administer treatments like those powered by CIL-Key™. About CILA Therapeutics CILA Therapeutics is a biotechnology company focused on improving lung health through transformative, scalable, accessible therapies and technologies that easily integrate into patients' daily lives. Its vision is to empower people with pulmonary diseases to breathe easily and live fully. CILA's pipeline includes first-in-class inhaled therapeutics and CIL-Key™, a proprietary platform to enhance delivery of RNA-based therapeutics and vaccines targeting a wide spectrum of pulmonary diseases. Visit CILA is actively seeking strategic partnerships to expand the platform's application across diverse RNA-based pipelines for rare and common pulmonary indications.

O.C. Tanner Launches Buy Up, Offering New Ways to Earn and Claim Awards
O.C. Tanner Launches Buy Up, Offering New Ways to Earn and Claim Awards

Business Wire

time6 minutes ago

  • Business Wire

O.C. Tanner Launches Buy Up, Offering New Ways to Earn and Claim Awards

SALT LAKE CITY--(BUSINESS WIRE)-- O.C. Tanner, the global leader in employee recognition and workplace culture solutions, proudly announces the launch of Buy Up, a new feature designed to make rewarding employees easier, more flexible, and more impactful than ever. 'The purpose of recognition programs is to motivate, inspire, and help people thrive at work,' said Chief Product Officer Dave Hilton. 'Buy Up only builds on that purpose by providing greater freedom for employees to engage with their recognition platform. I'm proud of our team for continuing to innovate at the intersection of appreciation and technology.' Buy Up is a new feature within O.C. Tanner's Culture Cloud platform, an employee recognition solution to help companies appreciate great work. With Buy Up, employees around the world can now enhance their recognition experience by electing to add points to their existing balance of credits for great work to enable a faster path to the reward they want. The feature is available at any time in Culture Cloud's award store and activates automatically when a user's cart exceeds their available point balance, creating a convenient way for the recipient to receive the awards they want most. Designed with flexibility and scalability in mind, Buy Up supports global transactions while ensuring data security. O.C. Tanner does not store or access payment information, and there are no processing fees from the company. For more information about O.C. Tanner's complete recognition platform, Culture Cloud, visit About O.C. Tanner O.C. Tanner is the global leader in software and services that improve workplace culture through meaningful employee recognition experiences. Our Culture Cloud employee recognition platform helps millions of people thrive at work. Our team of more than 1,500 programmers, researchers, designers, client professionals, and craftspeople hail from 58 countries and speak 62 languages. Together, we create the technology, tools, and awards that help our clients shape productive work environments, drive innovation, and fuel positive business results. Learn more at

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store